B01AC13 - Abciximab

Not Porphyrinogenic

Rationale

Polypeptide. No CYP-interactions.

Chemical description

Fab-fragment of the chimeric monoclonal antibody 7E3, binds to and blocks a platelet surface receptor. Used together with ASA and heparin as i.v. infusion 0.25 mg/kg BW, in percutaneous coronary intervention.

Similar drugs

Explore alternative drugs in similar therapeutic classes

B01A ANTITHROMBOTIC AGENTS
B01AC Platelet Aggregation Inhibitors Excl. Heparin

References

Tradenames

Show more details and information about the listed tradenames

ReoPro

Reopro

Abciximab

In cooperation with Ipnet

Acute Porphyria Drugs

B01AC13 - Abciximab